Commercial Activist investor renews its criticism of Novavax PharmaphorumShah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."CommercialRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaphorum Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.” CommercialRead full story Post navigation Previous: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make HeadwayNext: Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
